Equities analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will report earnings per share (EPS) of ($0.78) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Ascendis Pharma A/S’s earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at ($0.69). Ascendis Pharma A/S reported earnings per share of ($0.60) during the same quarter last year, which would suggest a negative year-over-year growth rate of 30%. The company is scheduled to report its next quarterly earnings report on Wednesday, August 30th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.32) to ($2.90). For the next year, analysts expect that the business will post earnings of ($2.82) per share, with EPS estimates ranging from ($3.39) to ($2.33). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, May 23rd. The biotechnology company reported ($0.83) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.19. The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $1.10 million. Ascendis Pharma A/S had a negative net margin of 1,944.88% and a negative return on equity of 58.53%.
A number of equities analysts recently issued reports on ASND shares. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday, February 23rd. Leerink Swann cut shares of Ascendis Pharma A/S from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $24.00 to $30.00 in a research note on Thursday, March 9th. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th. ValuEngine upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Saturday, May 27th. Finally, J P Morgan Chase & Co started coverage on shares of Ascendis Pharma A/S in a research note on Thursday, May 11th. They issued an “overweight” rating and a $36.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $29.60.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded up 3.45% during mid-day trading on Monday, hitting $24.00. 54,135 shares of the stock traded hands. The company’s market capitalization is $780.05 million. Ascendis Pharma A/S has a 1-year low of $12.34 and a 1-year high of $31.86. The company’s 50-day moving average price is $25.93 and its 200 day moving average price is $24.96.
A number of institutional investors have recently modified their holdings of ASND. FMR LLC raised its position in shares of Ascendis Pharma A/S by 25.5% in the fourth quarter. FMR LLC now owns 3,152,532 shares of the biotechnology company’s stock worth $63,807,000 after buying an additional 639,708 shares during the period. EcoR1 Capital LLC raised its position in shares of Ascendis Pharma A/S by 345.1% in the fourth quarter. EcoR1 Capital LLC now owns 975,700 shares of the biotechnology company’s stock worth $19,748,000 after buying an additional 756,500 shares during the period. Deerfield Management Co. acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $21,252,000. Eventide Asset Management LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $4,635,000. Finally, Marshall Wace LLP acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $1,772,000. 65.19% of the stock is owned by institutional investors and hedge funds.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230824/zacks-analysts-expect-ascendis-pharma-as-asnd-will-post-earnings-of-0-78-per-share.html
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.